Industry wants more transparency, dedicated program for complex generics in GDUFA IV
Regulatory NewsJoanne S. Eglovitch
GDUFAGenericsHealth Authority meeting and communication strategyProduct developmentRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)User fees